Millipore Sigma Vibrant Logo

AB947 Anti-Apolipoprotein E Antibody

View Products on
1 mL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited Availability
Limited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers


      Contact Customer Service


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, PmIHC, WBGtSerumPolyclonal Antibody
      Catalogue NumberAB947
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Apolipoprotein E Antibody
      Alternate Names
      • ApoE
      Product Information
      • Liver tissue
      PresentationDelipidated goat antiSerum, 0.2 μm filtered. Liquid in Tris-saline, pH 7.4 with 0.1% sodium azide as preservative.
      Quality LevelMQ100
      ApplicationDetect Apolipoprotein E using this Anti-Apolipoprotein E Antibody validated for use in IH & WB.
      Key Applications
      • Immunohistochemistry
      • Western Blotting
      Application NotesWestern blot (Schwab, 1996): 1:1,000-1:2,000

      Immunohistochemistry (Summers, 1998; Wisniewski & Frangione, 1992; Schwab, 1996)

      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenRecombinant human apolipoprotein E.
      SpecificityMonospecific for Apolipoprotein E by immunoelectrophoresis when tested against pooled human plasma and twice concentrated pooled human serum. Reacts with Apo E isoforms E2, E3 and E4 by Western blot.
      Species Reactivity
      • Human
      • Primate
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryChylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
      Gene Symbol
      • APOE
      • Apo-E
      • apoprotein
      • MGC1571
      • AD2
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02649 # Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
      SIZE: 317 amino acids; 36154 Da
      TISSUE SPECIFICITY: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
      PTM: Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. & Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
      DISEASE: SwissProt: P02649 # Defects in APOE are a cause of hyperlipoproteinemia type III [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with hyperlipoproteinemia type III, are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of hyperlipoproteinemia type III have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. & The APOE*4 allele is associated with late onset Alzheimer disease 2 (AD2) [MIM:104310]. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. & Defects in APOE are a cause of sea-blue histiocyte disease [MIM:269600]; also called sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
      SIMILARITY: SwissProt: P02649 ## Belongs to the apolipoprotein A1/A4/E family.
      Molecular Weight34 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size1 mL
      Transport Information
      Supplemental Information


      Anti-Apolipoprotein E Antibody SDS


      Safety Data Sheet (SDS) 

      Anti-Apolipoprotein E Antibody Certificates of Analysis

      TitleLot Number
      GOAT ANTI-APOLIPOPROTEIN E - 2488747 2488747
      GOAT ANTI-APOLIPOPROTEIN E - 2510138 2510138
      GOAT ANTI-APOLIPOPROTEIN E - 3170883 3170883
      GOAT ANTI-APOLIPOPROTEIN E - 3238416 3238416
      GOAT ANTI-APOLIPOPROTEIN E - 3385779 3385779
      GOAT ANTI-APOLIPOPROTEIN E - 3524799 3524799
      GOAT ANTI-APOLIPOPROTEIN E - 3807897 3807897


      Reference overviewPub Med ID
      Quantitative proteomics identifies host factors modulated during acute hepatitis E virus infection in the swine model.
      Rogée, S; Le Gall, M; Chafey, P; Bouquet, J; Cordonnier, N; Frederici, C; Pavio, N
      Journal of virology  89  129-43  2015

      Show Abstract
      25320303 25320303
      Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
      Hu, J; Liu, CC; Chen, XF; Zhang, YW; Xu, H; Bu, G
      Molecular neurodegeneration  10  6  2015

      Show Abstract
      25871773 25871773
      The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles.
      Boyer, A; Dumans, A; Beaumont, E; Etienne, L; Roingeard, P; Meunier, JC
      The Journal of biological chemistry  289  18904-13  2014

      Show Abstract
      24838241 24838241
      Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins.
      Lee, JY; Acosta, EG; Stoeck, IK; Long, G; Hiet, MS; Mueller, B; Fackler, OT; Kallis, S; Bartenschlager, R
      Journal of virology  88  12422-37  2014

      Show Abstract
      25122793 25122793
      Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90.
      Bukong, TN; Momen-Heravi, F; Kodys, K; Bala, S; Szabo, G
      PLoS pathogens  10  e1004424  2014

      Show Abstract
      25275643 25275643
      Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.
      Roher, AE; Maarouf, CL; Malek-Ahmadi, M; Wilson, J; Kokjohn, TA; Daugs, ID; Whiteside, CM; Kalback, WM; Macias, MP; Jacobson, SA; Sabbagh, MN; Ghetti, B; Beach, TG
      American journal of neurodegenerative disease  2  187-207  2013

      Show Abstract
      24093083 24093083
      Molecular Differences and Similarities Between Alzheimer's Disease and the 5XFAD Transgenic Mouse Model of Amyloidosis.
      Maarouf, CL; Kokjohn, TA; Whiteside, CM; Macias, MP; Kalback, WM; Sabbagh, MN; Beach, TG; Vassar, R; Roher, AE
      Biochemistry insights  6  1-10  2013

      Show Abstract
      25210460 25210460
      Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures.
      Gorham, RD; Forest, DL; Tamamis, P; López de Victoria, A; Kraszni, M; Kieslich, CA; Banna, CD; Bellows-Peterson, ML; Larive, CK; Floudas, CA; Archontis, G; Johnson, LV; Morikis, D
      Experimental eye research  116  96-108  2013

      Show Abstract
      23954241 23954241
      Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease.
      Takeda, S; Hashimoto, T; Roe, AD; Hori, Y; Spires-Jones, TL; Hyman, BT
      FASEB journal : official publication of the Federation of American Societies for Experimental Biology  27  3239-48  2013

      Show Abstract
      23640054 23640054
      Role of low-density lipoprotein receptor in the hepatitis C virus life cycle.
      Albecka, Anna, et al.
      Hepatology, 55: 998-1007 (2012)  2012

      Show Abstract
      22121002 22121002

      Related Products & Applications

      Related Products

      Catalog Number Description  
      ABN1350 Anti-ApoE4 Fragment nApoECF Antibody (Asp172) Show Pricing & Availability
      MABN43 Anti-Apolipoprotein E4 (ApoE4) Antibody, clone 4E4 Show Pricing & Availability

      Alternative Packsize

      Catalog Number Description  
      AB947-K Anti-Apolipoprotein E (1L) Show Pricing & Availability

      Product Families


      Life Science Research > Antibodies and Assays > Primary Antibodies